StockNews.com assumed coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH – Free Report) in a report released on Friday. The brokerage issued a hold rating on the biotechnology company’s stock.
Bellerophon Therapeutics Price Performance
Shares of NASDAQ BLPH opened at $0.01 on Friday. The stock has a market capitalization of $146,796.00, a P/E ratio of -0.01 and a beta of 0.74. Bellerophon Therapeutics has a one year low of $0.01 and a one year high of $0.02. The firm’s 50 day simple moving average is $0.03 and its two-hundred day simple moving average is $0.04.
Bellerophon Therapeutics Dividend Announcement
The firm also recently declared a dividend, which was paid on Wednesday, December 18th. Shareholders of record on Friday, December 20th were paid a $0.019 dividend. This represents a yield of 117.8%. The ex-dividend date of this dividend was Thursday, December 19th.
About Bellerophon Therapeutics
Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.
Featured Stories
- Five stocks we like better than Bellerophon Therapeutics
- 3 Tickers Leading a Meme Stock Revival
- Cold Front, Hot Stocks: Diesel Prices Propel Energy Leaders
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Sustainable and Successful: 3 Climate ETFs Beating the Market
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Quantum Opportunity: Skywater Technology’s Long-Term Potential
Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
